Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Mitoxantrone-induced suicidal erythrocyte death.
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
Impact of MS during the critical window of brain development.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
European Medicines Agency
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

Pages